Astrogen is developing AST-001, a treatment for pediatric autism spectrum disorder that modulates synaptic pruning to regulate excessive neural network development in children aged 2 to 11. This drug addresses the unmet medical need for effective therapies in a condition that currently lacks approved pharmacological options.
Funding
Funding not disclosed
Founders
Product
Problem
Autism spectrum disorder (ASD) in children aged 2 to 11 is characterized by excessive neural network development, leading to difficulties in social interaction, communication, and repetitive behaviors. There is a significant unmet medical need for therapies that address the core symptoms of ASD, as current treatments primarily focus on managing associated symptoms.
Solution
Astrogen is developing AST-001, a therapeutic intervention designed to modulate synaptic pruning and regulate neural network development in children with ASD. AST-001 aims to improve core ASD symptoms, particularly social interaction and communication skills, with a favorable safety profile. The drug has shown statistically significant improvements in clinical trials, including Phase 2 studies demonstrating enhanced social adaptive behavior and communication skills. Astrogen is currently conducting a Phase 3 clinical trial across multiple university hospitals to further evaluate the efficacy and safety of AST-001, with plans to pursue conditional approval to expedite its availability to patients.
Target Audience
The primary target audience includes children aged 2 to 7 diagnosed with autism spectrum disorder and their families, as well as pediatric neurologists and healthcare providers specializing in neurodevelopmental disorders.
Features
- AST-001 is designed to modulate synaptic pruning, addressing the underlying neurological mechanisms of ASD.
- Clinical trials have demonstrated statistically significant improvements in social adaptive behavior, as measured by the Vineland Adaptive Behavior Scales.
- Studies have shown improvements in communication skills and social responsiveness, including increased eye contact and response to name.
- The therapeutic is designed to have a favorable safety profile with minimal adverse effects.
- AST-001 has received orphan drug designation, which provides regulatory support and potential market exclusivity.
- The company is collaborating with global GMP-certified manufacturers to ensure high-quality drug production for clinical trials and potential commercialization.